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O-GlcNAcylation is a covalent attachment of a single N-acetyl 
glucosamine to a serine or threonine residue of a protein. Unlike other forms of 
protein glycosylation, there is no chain elongation in O-GlcNAcylation. O-GlcNAc 
transferase (OGT) adds O-GlcNAcase (OGA) removes O-GlcNAc from a protein. 
The process of O-GlcNAcylation is dynamic and has extensive crosstalk with 
protein phosphorylation. O-GlcNAcylation plays an important role in cell cycle 
progression, metabolic disorders, cancer, and responses to various stressors. 
The role of O-GlcNAc in liver injury and regeneration has not been clearly 
defined. Due to the wide array of cellular processes and pathologies that involve 
O-GlcNAc and the knowledge gap in liver injury and regeneration, we set out to 
determine the role O-GlcNAc plays in liver injury and regeneration. 
 APAP is the most widely used over-the-counter analgesic and antipyretic 
in the western world. Overdose of APAP leads to GSH depletion and 
centrilobular liver damage. First, we looked at the role of O-GlcNAc in response 
to APAP overdose in mice using both a decrease and an increase in O-
GlcNAcylation. Hepatocyte specific deletion of OGT (OGT KO) in mice was used 
to decrease O-GlcNAcylation. OGT KO mice and WT mice were treated with 300 
mg/kg APAP and the development of liver injury was studied over a time course 
of 0-24 hr. OGT KO mice showed dramatic decrease in liver injury compared to 
wild type mice. Serum ALT levels were markedly decreased in all time points in 
OGT KO mice and immunohistochemistry showed no centrilobular necrosis or 
cell death. OGT KO mice showed decrease in APAP-Cys protein adducts. There 
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was no difference in CYP2E1 protein levels or activity and initial GSH depletion 
between OGT KO and WT mice. There was rapid replenishment of GSH in OGT 
KO mice and induction of enzyme critical to GSH biosynthesis and recycling. 
Treatment with Thiamet-G (TMG), a potent inhibitor of OGA, was used to model 
a increase in O-GlcNAcylation. C57BL/6J mice were treated acutely with 400 
mg/kg TMG 1.5 hr after APAP treatment. TMG treated mice showed an increase 
in APAP-induced liver injury as seen by Serum ALT immunohistochemistry. 
Acute TMG treatment also induced a prolonged JNK activation. Treatment with 
acute TMG did not affect hepatic CYP2E1 levels, APAP-protein adducts, and 
APAP-induced mitochondrial damage. Whereas GSH depletion was not different, 
GSH replenishment and GSH biosynthesis genes were lower in TMG-treated 
mice after APAP overdose.  
 Next, we examined the effects of OGT KO on liver regeneration after 
partial hepatectomy (PHX). WT mice had normal regeneration that subsided at 7 
days post PHX. OGT KO mice showed normal regeneration up to 48 hr post 
PHX, but exhibited significant increase in liver regeneration from 5-14 days post 
PHX. OGT KO mice had higher liver to body weight ratio at 7 and 14 days and 
several pathways known to be critical in liver regeneration remained active out to 
14 days post PHX. Indicative of an increase in proliferation, protein associated 
with cell cycle and cell cycle progression such as Cyclin D1, A2, B1, pRb, and 
CDK4 levels were all elevated at later time points. HNFα was decreased at 14 
days, and several genes knows to be down regulated by HNF4a had increased 
fold change as seen in RNA-Seq data. Taken together, this data shows that OGT 
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KO increases liver regeneration after PHX and leads to a loss of termination of 
liver regeneration. 
 Overall, these studies show that O-GlcNAcylation plays a central role in 
liver injury and regeneration, and could potential lead to therapeutic interventions 
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Chapter 1- Introduction 
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1.1 O-GlcNAc  
N-acetyl glucosamine (O-GlcNAc) was discovered over 30 years ago, in 
1983, by Drs. Torres and Hart at the Johns Hopkins School of Medicine (Torres 
and Hart 1984). Since this discovery, there have been many new and exciting 
findings in the field of O-GlcNAcylation, and this little single sugar-mediated 
posttranslational modification has proven to be quite a big player. O- 
GlcNAcylation is the dynamic covalent attachment of an O-GlcNAc moiety to a 
serine or threonine residue of nuclear, cytoplasmic and mitochondrial proteins 
(Zachara, O'Donnell et al. 2004, Slawson, Copeland et al. 2010). Unlike other 
forms of glycosylation there is no chain elongation of the sugar into more 
complex oligosaccharides and it is only found in the intracellular compartment, 
and thus is not found at the cell surface or in the extracellular space (Slawson 
and Hart 2011). O-GlcNAc cycling also differs from traditional forms of protein 
glycosylation in that it is dynamic, meaning there is rapid cycling of O-GlcNAc on 
and off proteins. To date, no consensus binding sequence or motif for O-GlcNAc 
has been identified; but that has not stopped the identification of over 4000 
proteins that are modified by O-GlcNAc with the development of modern mass 
spectrometry (MS) techniques (Ma and Hart 2014).   
O-GlcNAc is the end product of the hexosamine biosynthetic pathway 
(HBP) (Fig.1.1.1). Flux through the HBP is determined by glucose uptake in the 
cell. Glucose molecules that enter glycolysis are converted to glucose-6-
phosphate by the enzyme hexokinase. Glucose-6-phosphate is then isomerized 
to fructose-6-phosphate by Glucose-6-phosphate isomerase, of which a portion 
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enters the HBP (Teo, Wollaston-Hayden et al. 2010). Around 2-3% of all cellular 
glucose enters the HBP and the final product of the pathway is the high-energy 
donor substrate UDP-GlcNAc (Slawson, Copeland et al. 2010, Bond and 
Hanover 2015). Flux through the HBP is controlled by a rate-limiting enzyme 
glutamine fructose-6-phosphate amidotransferase, or GFAT, and feedback 
inhibition through the production of UDP-GlcNAc. HBP it at a crucial junction of 
cell metabolism pathways including protein, carbohydrate, lipid, and nucleotide 
metabolisms; as well as energy changes due to the need of ATP required to run 
the pathway (Hanover, Krause et al. 2012). Because of its location downstream 
of so many processes central to the function of the cell, O-GlcNAc and flux 
through the HBP are often thought to be a nutrient sensor (Butkinaree, Park et al. 
2010). The availability of glucose can control the amount of O-GlcNAcylation 
seen on intracellular proteins, and in turn O-GlcNAcylation is sensitive in 
changes to glucose metabolism. It has been shown that O-GlcNAc levels 
attenuate insulin signaling and contribute to the mechanism by which increased 
flux through the HBP leads to insulin resistance in adipocytes (Vosseller, Wells et 
al. 2002).     
O-GlcNAc cycling also differs from traditional forms of protein 
glycosylation in that it is dynamic, meaning there is rapid cycling of O-GlcNAc on 
and off proteins. The actual process of O-GlcNAcylation, the addition of O-
GlcNAc to the protein backbone using UDP-GlcNAc as a substrate, is performed 
by two specific enzymes O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). 
OGT is located on the X chromosome and is a highly conserved protein that 
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exists in mammals in three isoforms that only differ in the amount of 
tetratricopeptide repeats (TPRs)- the nucleocytoplasmic (ncOGT), the short 
isoform (sOGT) and the mitochondrial form (mOGT) (Shafi, Iyer et al. 2000, 
Lazarus, Love et al. 2006, Hanover, Krause et al. 2012). OGA exists as two 
isoforms; the long (OGA-L), which contains a histone acetyl transferase domain 
(HAT), and the short (OGA-S) (Bond and Hanover 2015) (Fig.1.1.2). OGT is the 
only enzyme capable of adding O-GlcNAc, and conversely OGA is the only 
enzyme that removes O-GlcNAc. This specificity of enzymes for addition and 









Fig.1.1.1. A schematic representation of the hexosamine biosynthetic pathway 
(HBP) and how it integrates many other cellular processes. Glucose enters the 







Fig.1.1.2. (A) The three isoforms of OGT showing the variable TPR repeats- 
ncOGT (12 TPRs), mOGT (9 TPRs) and sOGT (2 TPRs). (B) The two isoforms of 
OGA- OGA-L with a HAT domain and OGA-S without a HAT domain.  
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Extensive studies show that O-GlcNAc has cross talk with protein 
phosphorylation in many signaling pathways (Wang, Gucek et al. 2008, Zeidan 
and Hart 2010). O-GlcNAcylation sites have been found to be identical or 
proximal to the same serine and threonine phosphorylation sites used by kinases 
(Hart, Slawson et al. 2011). When O-GlcNAc is elevated in mammalian cells, 
70% of phosphorylation sites are affected, making it extremely important in 
signaling cascades and enzyme function (Wang, Gucek et al. 2008). The 
relationship between O-GlcNAcylation and protein phosphorylation is so 
interlinked that both OGT and OGA often occur in complexes that contain both 
kinases and phosphatases (Slawson, Lakshmanan et al. 2008, Zeidan and Hart 
2010). Because of this close relationship with protein phosphorylation, O-
GlcNAcylation can affect many cellular processes regulated by phosphorylation. 
The O-GlcNAcylation of proteins is dynamic and often times a response to 
cellular stress, where a wide variety of cellular stresses lead to a rapid increase 
in the O-GlcNAcylation of nuclear and cytoplasmic proteins (Zachara, O'Donnell 
et al. 2004). It has also been shown that mitogenic activation of T lymphocytes 
induces a rapid change in both nuclear and cytosolic O-GlcNAcylation (Kearse 
and Hart 1991). O-GlcNAc levels are important regulators of the cell cycle and 
are involved in cell cycle progression, controlling mitotic phosphorylation, 
regulation of cyclin expression, and cytokinesis (Slawson, Zachara et al. 2005). 
O-GlcNAc plays a very important role in many cellular processes including organ 
development (Hanover, Krause et al. 2012), cancer pathogenesis (Slawson and 
Hart 2011), stress response (Chatham and Marchase 2010) and tau 
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phosphorylation (Yu, Zhang et al. 2012). It has been shown that O-GlcNAcylation 
is crucial for embryonic development. For example, deletion of OGT leads to loss 
of embryonic stem cell viability (Shafi, Iyer et al. 2000). O-GlcNAc also plays a 
key role in many cancers, including breast, lung, colon, and prostate cancer 
(Slawson and Hart 2011, Ferrer, Sodi et al. 2016). O-GlcNAcylation has also 
been shown to be critical in Alzheimer’s disease (Zhu, Shan et al. 2014), 
cardiovascular disease (Zachara 2012), and the metabolic syndromes and 
diabetes (Ma and Hart 2013). A brief list of target organs or systems affected by 
O-GlcNAc is shown in Fig.1.1.3 to outline the wide-reaching effects of O-GlcNAc 
on cellular function.   
O-GlcNAc has also been shown to be involved in mitochondrial function 
and oxidative stress (Love, Kochan et al. 2003, Tan, Villar et al. 2014). Altering 
the cycling of O-GlcNAc also has profound effects on the mitochondrial function 
and the respiratory chain (Tan, Villar et al. 2014). In mice, a knockout of OGT 
leads to impaired mitochondrial function, increased reactive oxygen species 
levels and activation of the main antioxidant defense gene NRF2 (Tan, McGreal 
et al. 2017). The relationship between O-GlcNAc and oxidative stress could 
prove to be of critical importance after exposure to a toxicant, such as 
acetaminophen, that depletes antioxidants, specifically glutathione (GSH).   
O-GlcNAc is also important for the cell cycle and cell cycle progression.  
Elevated O-GlcNAc is a key regulator of mitotic phosphorylation, leads to cell 
growth delays of many cell types, and the overexpression of either OGT or OGA 
disrupts cyclin periodicity and causes improper cytokinesis (Slawson, Zachara et 
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al. 2005). The coordinated cycling of O-GlcNAc by OGT and OGA is required to 
regulate mitotic spindle formation, where an increase in O-GlcNAc cycling leads 
to improper mitotic spindles formation (Tan, Caro et al. 2013). In mouse 
embryonic fibroblasts, the deletion of OGT leads to an increase in the expression 
of the cyclin inhibitor p27, growth delays and eventual cell death (O'Donnell, 
Zachara et al. 2004). Similarly, a stable knockdown of OGA in HeLa cells causes 
a prolonged M phase of the cell cycle leading to improper cytokinesis, shortened 
spindle chromatids and increased multi-polar spindles (Lanza, Tan et al. 2016). 
The alteration in the cell cycle shows that maintaining O-GlcNAc homeostasis is 
a critical component of proper cell cycle progression and completion.  
There are several different ways to modulate cellular O-GlcNAc levels. 
Pharmacologic agents, such as PUGNAc, Streptozotacin and Thiamet G (TMG) 
have been shown to inhibit the enzyme OGT and increase cellular levels of O-
GlcNAc (Macauley and Vocadlo 2010). TMG treatment has been shown to 
increase O-GlcNAcylation and decrease phosphorylation of tau proteins, a 
hallmark of Alzheimer’s disease (Yu, Zhang et al. 2012). This has led to the 
development of TMG as a possible treatment for Alzheimer’s disease. 
 Studies show that increasing flux through HBP can increase the levels of 
O-GlcNAc in the cell. Over the counter glucosamine has been shown to increase 
cellular O-GlcNAc levels and flux through the HBP (Tannock, Kirk et al. 2006). 
Glucosamine is able to bypass glutamine fructose-6-phosphate amidotransferase 
(GFAT), the rate-limiting enzyme of HBP (Teo, Wollaston-Hayden et al. 2010). 
Previous studies with glucosamine treatment have shown that supplementation 
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of diet or addition to drinking water (Tannock, Kirk et al. 2006) daily 
intraperitoneal injection (IP) (Song, Kang et al. 2014) and oral gavage (Carames, 
Kiosses et al. 2013) can increase cellular levels of O-GlcNAc. Modulation of O-
GlcNAc can also be done at a gene level by selective knockout of genes involved 
in the cycling of O-GlcNAc, specifically OGT. An OGT floxed mouse (OGTF) has 
been developed and the resulting knockout of OGT leads to a decrease in the 
levels of O-GlcNAc (Shafi, Iyer et al. 2000). The generation of an OGA knockout 
mouse shows that a deletion of OGA leads to defects in metabolic homeostasis 
and eventually obesity and insulin resistance (Keembiyehetty, Love et al. 2015). 
Due to the general ease by which cellular O-GlcNAc levels can be modulated 
and the great number of cellular processes O-GlcNAcylation is involved in, the 










Fig.1.1.3. A brief list of some of the organs and systems affected by O-GlcNAc 
biology, showing the wide-ranging processes that involve O-GlcNAcylation.  
Organ	or	System Effect Reference 
Brain 
Regulates Tau 
phosphorylation (Yu, Zhang et al. 2012) 
Alzheimer’s Disease (Zhu, Shan et al. 2014) 
Eye Diabetic Retinopathy 







Marchase et al. 2008) 
Increased O-GlcNAc 
inhibits inflammation in 
acute arterial injury 
(Xing, Feng et al. 2008) 
O-GlcNAc is 
indispensable in the failing 
heart 
(Watson, Facundo et al. 
2010) 
Liver Tumor recurrence in HCC (Zhu, Zhou et al. 2012) 
Colon 
Increased levels of O-
GlcNAc in colon cancer 
cells 




results in insulin 
resistance 





associated with increased 
insulin sensitivity in blood 
(Myslicki, Shearer et al. 
2014) 
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1.2 Acetaminophen-induced Acute Liver Failure 
Acetaminophen (APAP) is a safe over the counter analgesic and anti-
pyretic drug when used at therapeutics doses, but it can cause hepatotoxicity 
when taken in excess. In the United States, APAP overdose is the leading cause 
of drug induced acute liver failure (ALF), and APAP overdose accounts for more 
than 100,000 calls to poison control centers, 56,000 emergency room visits, 
2,600 hospitalizations and 500 deaths (Nourjah, Ahmad et al. 2006). APAP 
overdose cases can be divided into two categories; unintentional overdose, 
where the patient takes a large amount of APAP because they are unaware that 
several products contain APAP or they are not getting the desired pain relief, and 
intentional suicidal overdose (Lee 2004). The mechanism of APAP toxicity has 
been extensively studied over the decades, but the treatment options are still 
limited.  N-acetylcysteine, a glutathione precursor, is the only recognized 
pharmacological intervention, but it has only been shown to be effective when 
given in the early stages after APAP overdose (Yang, Miki et al. 2009). 
Ultimately, patients who overdose on APAP may be subject to a liver 
transplantation. Liver transplantation is complicated by lack of donor availability, 
graft rejection, cost and late presentation with rapid decline (Lee 2012).   
The majority of a dose of APAP is either glucuronidated or sulfated by 
phase II enzymes and excreted safely. A small portion of the dose is converted to 
the reactive metabolite N-acetyl-benzoquinone imine (NAPQI) by cytochrome 
P450 enzymes, with CYP2E1 being the primary enzyme in rodents. NAPQI can 
be conjugated to glutathione and excreted, but the glutathione stores are rapidly 
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depleted in an APAP overdose scenario. Once glutathione is depleted, NAPQI 
can bind to proteins to form protein adducts (McGill and Jaeschke 2013). If 
glutathione is depleted prior to dosing with APAP, there is impairment of the 
antioxidant defense system, and it has been show that providing N-
acetylcysteine during the initial injury period is protective against APAP-induced 
liver damage (James, McCullough et al. 2003, Saito, Zwingmann et al. 2010). It 
is known that APAP-induced liver injury involves a cascade of events following 
bio-activation of APAP to NAPQI including increased formation of reactive 
oxygen and reactive nitrogen species, JNK activation, mitochondrial damage and 
ultimately cellular necrosis (Jaeschke and Bajt 2006, Jaeschke, McGill et al. 

































Fig.1.2.1. A graphic representation of APAP metabolism leading to acute liver 
failure (ALF).  
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A major factor in the outcome on drug induced ALF is the innate ability of 
the liver to regenerate itself after insult or injury. The liver regenerates in 
response to hepatotoxicants such as APAP, carbon tetrachloride, chloroform, 
and thioacetamide (Mehendale 2005). After insult by APAP, the regeneration of 
the liver follows the dose response where increasing the dose increases the liver 
injury and there is also a proportionate increase in liver regeneration. This is 
followed up to a threshold dose, beyond which the liver loses the ability to 
regenerate and injury progresses. This principle of dose response is shown using 
a novel incremental dose model. Mice treated with 300 mg/kg APAP showing 
injury progression accompanied by marked increase in regeneration, while mice 
treated with 600 mg/kg APAP showed injury progression but had substantial 
inhibition of liver regeneration (Bhushan, Walesky et al. 2014). Liver regeneration 
after drug overdose is an essential factor in determining the final patient outcome 
and understanding the mechanisms behind the liver’s ability to regenerate is 
paramount to discovering new treatment options. 
 
1.3 Liver Regeneration 
The ability of the liver to regenerate after insult or partial resection has 
been known since the times of the ancients Greeks and can be seen in the telling 
of the myth of Prometheus. Liver regeneration is studied by two methods, partial 
hepatectomy (PHX) and insult by hepatotoxicants such as APAP. While both 
models of liver regeneration are useful, there are some distinct differences. 
Toxicant induced liver injury produced by APAP involves necrosis and 
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inflammation; which are absent in PHX. In PHX, all surviving hepatocytes 
undergo proliferation. In APAP induced liver failure, only the hepatocytes 
surrounding the necrotic zone regenerate to restore the liver tissue. 
As mentioned previously, the liver regenerates in response to partial 
hepatectomy (PHX) where approximately 70% of the liver is removed surgically. 
The events of liver regeneration after PHX occur in an orderly fashion over a time 
course from within the first 5 minutes to 7 days after surgery, with the 
hepatocytes in the remaining liver mass undergoes proliferation to restore the 
removed tissue (Michalopoulos 2007). All four major cells types of the liver 
undergo regenerations to restore the lost cell mass from PHX. Hepatocytes begin 
with one round of DNA replication with a peak at 24 hours after PHX, and are 
followed by biliary ductal cells and Kupffer cells that peak at 48 hours post PHX 
and sinusoidal endothelial cells that peak at 4 days post PHX (Michalopoulos and 
DeFrances 1997).  
There are two distinct schools of thought on how liver regeneration is 
initiated. The first is the priming and progression model developed by Nelson 
Fausto. Priming and progression involves cytokines, such as TNFα and IL-6, that 
prime the liver to leave G0 and enter G1 phase of the cell cycle; and growth 
factors such as HGF, EGF and TGF that cause the progression from G1 to M 
phases of the cell cycle (Fausto, Campbell et al. 2006). The second paradigm of 
liver regeneration is primary and secondary mitogens created by George 
Michalopoulos. Primary or direct mitogens, such as hepatocyte growth factor 
(HGF) and epidermal growth factor (EGF), are able to induce proliferation in 
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serum free media (Block, Locker et al. 1996). Secondary mitogens are all other 
molecules that assist in hepatocyte proliferation, but cannot induce proliferation 
on their own. These secondary mitogens include TNF (Webber, Bruix et al. 
1998), norepinephrine (Cruise, Houck et al. 1985), and estrogens (Ni and Yager 
1994). 
Although there is much known about the initiation of liver regeneration and 
the signaling cascade that follows PHX, there is very little known about the signal 
that terminates liver regeneration. Although the mechanism is not completely 
known, many factors have been implicated in the termination of liver 
regeneration. Previous studies have shown that the nuclear receptor HNF4α can 
suppress hepatocyte proliferation, and its deletion can result in increased 
hepatocyte proliferation and cancer (Bonzo, Ferry et al. 2012, Walesky, 
Gunewardena et al. 2012, Walesky, Edwards et al. 2013). ILK deletion in 
hepatocytes leads to increase in post-PHX liver mass, leading to the conclusion 
that the extra cellular matrix mediated signaling driven by ILK is critical in the 
termination of liver regeneration (Apte, Gkretsi et al. 2009). Hippo/Yap signaling 
is known to help maintain organ size and development (Zhao, Tumaneng et al. 
2011). Over activation of Yap, i.e. the loss of phosphorylation of Yap, by Mst1/2 
deficiency leads to massive liver overgrowth and cancer (Zhou, Conrad et al. 
2009). There are many factors that can alter the state of termination during liver 




1.4 Purpose and Aims 
O-GlcNAcylation plays such an important role in a wide variety of cellular 
processes and O-GlcNAcylation is thought to be important in the treatment and 
pathogenesis of many diseases including Alzheimer’s disease (Macauley and 
Vocadlo 2010), recurrence of hepatocellular carcinoma (HCC) after liver 
transplantation (Zhu, Zhou et al. 2012) and metabolic disorder and diabetes 
(Wang, Park et al. 2009, Myslicki, Shearer et al. 2014). However, the role of O-
GlcNAcylation in APAP-induced acute liver failure and liver regeneration after 
partial hepatectomy has not been studied. This is important because of possible 
drug interactions between a wide variety of medications that contain APAP and 
over the counter supplements such as Glucosamine that can increase cellular O-
GlcNAc levels. It is highly likely that supplements that increase O-GlcNAc levels 
may affect the safety of APAP. Furthermore, because O-GlcNAcylation is a 
ubiquitous process, it is highly likely to be involved in hepatocellular injury and 
regeneration, which has not been investigated. Thus, these studies are important 
both from drug safety and a basic biology standpoint.   
The long-term goal of this project is twofold; 1- to clearly define the role O-
GlcNAc plays in acute liver injury after APAP overdose and 2- to clearly define 






Specific Aim #1: Determine the role of O-GlcNAcylation after APAP overdose 
• Determine the effects of an increase in O-GlcNAcylation on liver injury by 
treating C57Bl/6J mice with 300 mg/kg of APAP followed 1.5 hr later with 
400 mg/kg TMG. 
• Determine the effects of chronic O-GlcNAcylation on liver injury treating 
C57Bl/6J mice with 50 mg/kg TMG every other day for 15 days followed 
by 300 mg/kg of APAP. 
• Determine the effects on liver injury after a decrease in O-GlcNAcylation 
using OGTF mice. Induce a knockout of OGT using AAV8.TBG.Cre virus 
in hepatocytes and treat mice 10 days later with 300 mg/kg APAP. 
We hypothesize that any alteration if O-GlcNAcylation will have profound effects 
on the safety of APAP, with an increase in global O-GlcNAc increasing liver 
damage after APAP and a decrease in global O-GlcNAcylation leading to a 
decrease in APAP induced liver damage. 
 
Specific Aim #2: Determine the role of O-GlcNAcylation in liver regeneration after 
partial hepatectomy (PHX) 
• Determine the effects of a decrease in O-GlcNAcylation on the livers 
ability to regenerate after PHX using OGTF mice. Induce a knockout of 
OGT using AAV8.TBG.Cre virus in hepatocytes and perform PHX 10 days 
later.  
We hypothesize that a decrease in O-GlcNAcylation will adversely alter liver 







Chapter 2- Modulation of O-GlcNAc levels in the liver impacts 
acetaminophen-induced liver injury by affecting protein adduct formation 





Overdose of acetaminophen (APAP) results in acute liver failure. We have 
investigated the role of a post-translational modification of proteins called O-
GlcNAcylation, where the O-GlcNAc transferase (OGT) adds and O-GlcNAcase 
(OGA) removes a single b-D-N-acetylglucosamine (O-GlcNAc) moiety, in the 
pathogenesis of APAP-induced liver injury. Hepatocyte specific OGT knockout 
mice (OGT KO), which have reduced O-GlcNAcylation, and WT controls were 
treated with 300 mg/kg APAP and the development of injury was studied over a 
time course from 0-24 hr. OGT KO mice showed a dramatic decrease in liver 
injury as compared to WT mice. Whereas, there was no difference in CYP2E1 
activity or GSH depletion following APAP treatment in OGT KO mice, 
replenishment of GSH and induction of GSH biosynthesis genes were 
significantly faster in WT mice. Next, male C57BL/6J mice were treated Thiamet-
G (TMG), a specific inhibitor of OGA to induces O-GlcNAcylation, 1.5 hr after 
APAP administration and the development of liver injury was studied over a time 
course of 0-24 hr. TMG treatment resulted in significant increase in hepatic O-
GlcNAcylation. TMG-treated mice exhibited significantly higher APAP-induced 
liver injury as indicated by an increase in serum transaminase levels and 
histopathological analysis, as well as a prolonged JNK activation. Treatment with 
TMG did not affect hepatic CYP2E1 levels, APAP-protein adducts, and APAP-
induced mitochondrial damage. Whereas GSH depletion was not different, GSH 
replenishment and GSH biosynthesis genes were lower in TMG-treated mice 
after APAP overdose. Taken together, these data indicate that induction in 
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cellular O-GlcNAcylation exacerbates APAP-induced liver injury via dysregulation 





Overdose of acetaminophen (APAP) is the most common cause of acute 
liver failure (ALF) in the developed countries (Nourjah, Ahmad et al. 2006, Lee 
2008). Treatment options for APAP-induced ALF are extremely limited (Lee 
2008). Despite extensive investigations the mechanisms of APAP-induced liver 
injury are not completely clear (Jaeschke and Bajt 2006, Han, Shinohara et al. 
2010, Jones, Lemasters et al. 2010, Jaeschke, McGill et al. 2012). In recent 
years, several types of post-translational modifications (PTM), which modulate 
pathophysiological processes via modifying protein function, have been 
described (Schrattenholz, Soskic et al. 2010, Anbalagan, Huderson et al. 2012). 
However, the role of PTMs in APAP-induced liver injury has not been 
investigated.  
One such PTM is O-GlcNAcylation where a single b-D-N-
acetylglucosamine (O-GlcNAc) moiety is added to serine/threonine residues of 
intracellular proteins (Slawson and Hart 2003, Hart, Housley et al. 2007, Slawson 
and Hart 2011). An enzyme called O-linked N-acetylglucosamine transferase 
(OGT) catalyzes O-GlcNAcylation using UDP-GlcNAc as the sugar donor 
(Fig.2.4.2A). In contrast, the enzyme O-GlcNAcase (OGA) removes O-GlcNAc 
from the proteins. Extensive studies have demonstrated that O-GlcNAcylation of 
proteins results in significant changes in protein function and is involved 
numerous cellular and pathological processes including organ development 
(Hanover, Krause et al. 2012, Liu, Li et al. 2012), cancer pathogenesis (Slawson 
and Hart 2011), the stress response (Chatham and Marchase 2010, Martinez, 
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Dias et al. 2017) and cellular proliferation (Slawson, Zachara et al. 2005, 
Slawson, Copeland et al. 2010). Recently, increased levels of O-GlcNAc have 
been shown to control tau phosphorylation in the mammalian brain, which could 
lead to a possible treatment for Alzheimer’s disease (Macauley and Vocadlo 
2010). Additionally, modulation of O-GlcNAc has been investigated as a possible 
treatment for many diseases (Macauley, Shan et al. 2010, Macauley and 
Vocadlo 2010). However, the effect of changes in hepatic O-GlcNAc levels on 
APAP toxicity has not been investigated.  
In this study, we investigated the effect of O-GlcNAcylation on APAP 
toxicity using two approaches to modulate cellular O-GlcNAc levels in vivo – a 
hepatocyte-specific OGT knockout mouse, which has significantly less O-
GlcNAcylation and treatment with Thiamet-G (TMG), an inhibitor of OGA, to 
increase the levels of O-GlcNAc. Our data indicate that the alteration of O-









2.3 Materials and Methods 
 
Animal and Tissue Preparation 
All animal studies were approved by and performed in accordance with the 
Institutional Animal Care and Use Committee at the University of Kansas Medical 
Center. OGT-floxed mice (Shafi, Iyer et al. 2000) were a gracious gift from 
Natasha Zachara at The Johns Hopkins School of Medicine and were used to 
generate hepatocyte specific OGT knockout mice (OGT KO). Two to three month 
old male OGT-floxed mice (n=3-5 mice per group per time point) were treated 
with Cre-recombinase driven by thyroxin binding globulin promoter carried by the 
AAV8 virus [AAV8.TBG.PI.Cre.rBG (Penn Vector Core, Philadelphia, PA)] at a 
5E11 virus particles per mouse 10 days before dosing with APAP. OGT-floxed 
mice treated with an AAV8 carrying eGFP were used as control. For experiments 
with Thiamet-G (TMG) (SD Chemmolecules LLC, Owings Mills, MD), 2-3 old 
month male C57BL/6J mice (n=3 to 5 per group per time point) purchased from 
Jackson Laboratories (Bar Harbor, ME) were used. All mice were fasted 
overnight and treated with 300 mg/kg APAP (Sigma, St. Louis, MO). APAP was 
dissolved in warm 0.9% saline and was administered intraperitoneally (i.p.). In 
acute TMG treatment studies, mice were divided in two groups after APAP 
treatment and injected with either 0.9% saline or 400 mg/kg TMG dissolved in 
0.9% saline, i.p., 1.5 hr after APAP treatment (Fig.2.4.1). In chronic TMG 
treatment studies, 2-3 month old male C57BL/6J mice were treated with 50 
mg/kg TMG every other day for 2 weeks before APAP treatment 24 hr after the 
last TMG dose. In TMG dose finding studies, mice were fasted for 12 hr, treated 
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with either 400 or 800 mg/kg TMG dissolved in 0.9% saline and euthanized 18 hr 
after TMG treatment. Livers and blood samples were collected and processed as 
described before (Borude, Edwards et al. 2012, Walesky, Gunewardena et al. 
2012). Briefly, mice were euthanized by cervical dislocation after anesthesia with 
isoflorane (Piramal Healthcare, Andhra Pradesh, India) at various time points 
over a time course of 0 to 24 hr following APAP treatment. Blood was collected 
via optic vein catheter and the liver was removed surgically. Liver samples were 
used for histopathology and serum ALT activities were measured as a marker of 
liver injury as described before (Borude et al., 2012).  
 
Staining procedures 
H&E staining was done on a Leica Autostainer XL and CV5030 cover slipper. 
Staining was conducted using 4 µm thick paraffin embedded liver samples as 
described previously (Borude et al., 2012). Oil Red O staining was performed 
using 8 µm frozen liver sections as described before (Borude et al., 2012). 
Necrosis scoring was performed as previously described (Bhushan, Walesky et 
al. 2014). Briefly, at least 5 high power fields (400x) were scored in H&E stained 
slides from 3-5 animals per group by an experienced pathologist. Slides were 
blinded to the observer. Scores were used for statistical analysis. 
 
Protein Isolation and Western Blot Analysis 
Proteins were isolated from liver samples and Western Blot analysis was 
performed using methods described previously (Borude et al., 2012). Briefly, 
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frozen liver tissue was taken out of storage in the -80°C and solubilized in RIPA 
buffer. 100 µg of protein was loaded onto a Bis-Tris 4-12% gel (Invitrogen) and 
ran for 90 minutes at 150V. Proteins were transferred to PVDF (Millipore) 
membrane for antibody detection. All primary and secondary antibodies used for 
Western Blot analysis in this study were purchased from Cell Signaling 
Technology (Danvers, MA) and Abcam (Cambridge, MA). OGT and OGA 
antibodies were a generous gift from Gerald Hart at the Johns Hopkins School of 
Medicine. A comprehensive list of all antibodies can be found in the table below. 
 
 
Real Time PCR 
 RNA was isolated using TRIzol (Thermo Fisher Scientific) in accordance 
with the manufacturer’s protocol and converted to cDNA as previously described 
(Wolfe, Thomas et al. 2011). Real Time PCR was run on a BioRad CFX384 
(Hercules, CA) using SYBR green PCR master mix (Applied Biosystems, Foster 
City, CA). All target genes were normalized to 18S ribosomal RNA and compared 
to 0 hr samples. A comprehensive list of primers can be found in the table below. 
 
 
Primary Antibody Company Product No. 
Total JNK Cell Signaling 3708 
p-JNK Cell Signaling 4668 
OGT Antibodies were a generous gift of Gerald Hart from 
Johns Hopkins School of Medicine OGA 
Anti-O-GlcNAc (RL2) Abcam ab2739 
Cyp2E1 Abcam ab151544 
Actin Abcam A2066 
GAPDH Cell Signaling 2118 
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Primer Pair Primer Sequence 
GCLC Forward- ATCTGCAAAGGCGGCAAC Reverse- ACTCCTCTGCAGCTGGCT 
GCLM Forward- AGGAGCTTCGGGACTGTATCC Reverse- GGGACATGGTGCATTCCAAAA 
GR Forward- GCCTTTACCCCGATGTATCACGCTGTG Reverse- TGTGAATGCCAACCACCTTTTCCTCTTTG 
 
Glutathione Assay (GSH) and APAP adduct measurements 
GSH and GSSG were measured in liver homogenates as previously 
described (Jaeschke and Mitchell 1990). APAP adducts were measured as 
described before (McGill, Lebofsky et al. 2013). 
 
CYP2E1 Assay 
 CYP2E1 activity was measured using a p-nitrophenol assay as described 
before (Wu and Cederbaum 2008). Briefly, microsomes were isolated from liver 
tissue and activity was measured by the hydroxylation of p-nitrophenol to p-
nitrocatechol by CYP2E1.  
 
Mass Spectrometry of APAP Metabolites 
Materials. The standards, acetaminophen, 3-(N-acetyl-L-cysteine-S-yl) 
acetaminophen, 4-acetaminophen glucuronide, acetaminophen glutathione, 4-
acetaminophen sulfate and 3-cysteinylacetaminophen, and the internal 
standards, acetaminophen-d4 and acetaminophen sulfate-d3, were purchased 
from Toronto Research Chemicals (Toronto, Canada). Other chemicals and 
solvents used were obtained from standard suppliers and were of reagent or 
analytical grade. 
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Standard and Sample Preparation. Stock solutions of acetaminophen and its 
conjugated metabolites were prepared at 1 mM in 50:50 water:methanol and 
stored at -20°C until use. All mouse serum samples were thawed on ice. Several 
serum samples from untreated mouse were pooled and used as blank matrix for 
preparation of the calibration curve. A 20 µl aliquot of mouse serum sample was 
added to 90 µl of methanol (containing 200 ng/ml of acetaminophen-d4 and 400 
ng/ml of acetaminophen sulfate-d3) to precipitate the proteins. Then, 70 µl of 
water and 20 µl of 50:50 water:methanol were added. Samples were vortexed for 
10 sec and centrifuged for 10 min at 13,400 × g and 4°C. The standards were 
prepared following the same procedure but replacing the 20 µl of 50:50 
water:methanol by 20 µl of working standards in 50:50 water:methanol. The 
calibration standards ranged from 0.5 µM to 75 µM for acetaminophen 
glutathione and 0.25 µM to 75 µM for all the other analytes. 
 
Analytical Methods. All samples were analyzed by LC-MS/MS with a Waters 
ACQUITY Ultra-Performance Liquid Chromatography (UPLC®) system interfaced 
by electrospray ionization with a Waters Quattro Premier XE triple quadropole 
mass spectrometer (Waters Corp., Milford, MA) operated in positive mode with 
multiple reaction monitoring (MRM) scan type. The following source conditions 
were applied:  3.0 kV for the capillary voltage, 120°C for the source temperature, 
350°C for the desolvation temperature, 50 l/hr for the source gas flow and 600 
l/hr for the desolvation gas flow. The following mass transitions and collision 
energies (CE) were used to detect the respective analytes: 152>110, CE = 15 V 
 30 
for acetaminophen; 313>208, CE = 20 V for 3-(N-acetyl-L-cysteine-S-yl) 
acetaminophen; 328>152, CE = 20 V for 4-acetaminophen glucuronide; 
457>140, CE =  22 V for acetaminophen glutathione; 232>152, CE = 15 V for 4-
acetaminophen sulfate; 271>140, CE = 24 V for 3-cysteinylacetaminophen; 
156>114, CE = 15 V for acetaminophen-d4 and 235>155 CE = 15 V for 
acetaminophen sulfate-d3. The different compounds were separated on a Waters 
UPLC® HSS T3 column (1.8 µm, 2.1 x 150 mm) maintained at 50°C and using a 
gradient at 0.4 ml/min flow rate of mobile phase A (6 mM ammonium acetate in 
water with 0.01% formic acid) and mobile phase B (methanol) as follows: 2% B 
held for 0.5 min, increased to 75% over 3.5 min followed by an increase to 98% 
over 0.5 min and held at 98% for 2.0 min. Acetaminophen and its metabolites 
were quantified by back calculation of a weighted (1/x), linear least squares 
regression. The regression fit used the analyte/internal standard peak area ratios 
calculated from the calibration. Acetaminophen-d4 was used as the internal 
standard for acetaminophen and acetaminophen sulfate-d3 was used as the 
internal standard for all the metabolites. The MS peaks were integrated using 
QuanLynx software (version 4.1, Waters Corp., Milford, MA). 
  
Statistical Analysis 
Data presented as bar graphs show the mean ± SE.  Statistical 
significance was calculated using Student’s t-test and values were considered 





Increased O-GlcNAcylation in livers after APAP overdose 
Increase in total liver lysate protein O-GlcNAcylation was observed 
between 3 to 24 hr after APAP treatment in all molecular weight proteins as 
indicated by Western blotting (Fig.2.4.2B). Increased in O-GlcNAcylation 
correlates with increased liver injury as measured by serum ALT levels 
(Fig.2.4.2C). To further determine the role of O-GlcNAcylation in liver injury 
following APAP overdose, we generated hepatocyte specific OGT KO mice as 
described in the methods. The deletion of OGT was confirmed by Western Blot 
analysis for total liver extracts (Fig.2.4.2D). A significant decrease in OGT and a 
concomitant decline in total O-GlcNAcylation were observed in OGT KO mice. 
The small amount of OGT left is most likely in the non-parenchymal cells of the 






Fig.2.4.1. Experimental design to test the effects of increased hepatic O-
GlcNAcylation on APAP toxicity. (A) Scheme showing experimental design to test 
the role of increased O-GlcNAcylation on APAP-induced liver injury (B) Western 
Blot analysis of total O-GlcNAc levels at 6, 12 and 24 hr after APAP treatment 
using total liver cell extracts from mice treated with APAP+saline or APAP+TMG 









Fig.2.4.2. Changes in O-GlcNAcylation after APAP overdose in mice. (A) 
Schematic showing O-GlcNAcylation of proteins, role of OGT and OGA, AAV8 
driven deletion of OGT resulting in lower cellular O-GlcNAc, and TMG-mediated 
OGA inhibition resulting in increased cellular O-GlcNAc. (B) Western blot 
analysis of O-GlcNAcylated proteins, OGT, and OGA using total mouse liver 
extracts at various time points after APAP treatment (300 mg/kg) to C57BL/6 
mice. (C) Line graph showing serum ALT (Left Y-axis) and densitometry analysis 
of hepatic O-GlcNAcylation Western blot (right Y-axis) in APAP treated mice. 
Densitometry was performed on total O-GlcNAc blots. The data were normalized 
to Actin blot densitometry. (D) Western blot analysis of OGT KO and WT mice 
showing a decrease in protein O-GlcNAcylation and decrease in OGT protein 
levels in the KO mice. 
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OGT KO mice are resistant to APAP-induced acute liver injury 
  
WT and OGT KO mice were treated with 300 mg/kg APAP. Serum ALT 
levels indicated a significant decrease in liver injury at 6, 12, and 24 hr post 
APAP treatment in OGT KO mice compared to WT mice (Fig.2.4.3A). These 
findings were corroborated by histopathological analysis by H&E staining 
(Fig.2.4.3B). WT mice showed extensive centrilobular necrosis as expected 
within 6 hours after APAP exposure. The OGT KO mice exhibited a moderate 
change in hepatic histology but no frank cell death based on the relationship 
between necrosis and ALT in the early stages of APAP induced liver injury. OGT 
KO mice also showed depletion of glycogen upon fasting as seen in PAS stained 
slides, but glycogen was rapidly replenished by 1 hr post APAP treatment 
(Fig.2.4.4). WT mice had ablation of glycogen upon treatment with APAP at 1 hr 





Fig.2.4.3. OGT KO mice have decreased liver injury compared to WT mice. (A) 
Serum ALT levels in mice treated with 300 mg/kg APAP from 0-24 hr after APAP 
treatment. (B) Representative photomicrographs of H&E stained liver sections 
from 300 mg/kg APAP treated mice at 0, 12, and 24 hr. *Indicates statistically 






Fig.2.4.4. PAS stain showing OGT KO has rapid depletion of glycogen upon 
fasting, but rapid replenishment after APAP treatment.  
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OGT KO mice did not have altered APAP metabolism 
 
To determine whether the lower liver injury in the OGT KO mice is due to 
decreased APAP metabolism we determined hepatic CYP2E1 activity, APAP 
metabolite levels and adduct formation. There was no difference in microsomal 
CYP2E1 activity as measured by p-nitrophenol assay between WT and OGT KO 
mice (Fig.2.4.5A). Interestingly, we observed significantly less APAP-protein 
adducts at 1 and 6 hr in the OGT KO compared to WT mice (Fig.2.4.5B). We 
further analyzed the APAP metabolite profile using LC-MS, which showed that 
OGT KO and WT had similar levels of APAP-glucuronide and APAP-sulfate at 1 
hr, but those levels were significantly decreased in OGT KO mice at 6 and 12 hr 
(Fig.2.4.5C-D). Studies have shown that hepatic JNK activation is a critical and 
indispensable step in APAP-induced liver injury (Du, Xie et al. 2015). Western 
Blot analysis showed no increase in activation of JNK by phosphorylation (p-















Fig.2.4.5. OGT KO mice have no alteration in CYP2E1 levels but have changes 
in APAP metabolite formation. (A) p-Nitrophenol assay for CYP2E1 activity from 
isolated liver microsomes. (B) APAP-Cys protein adduct formation in whole liver 
lysate in mice treated with 300 mg/kg APAP at 0, 1, and 6 hr. LC-MS data 
showing (C) APAP-Glucuronide, and (D) APAP-Sulfate. (E) Western Blot of total 
and phosphorylated JNK activation using total liver extracts of mice treated with 
300 mg/kg APAP from 0-24 hr after APAP treatment. *Indicates statistically 




OGT KO mice had rapid replenishment of hepatic glutathione 
 GSH is the main cellular antioxidant molecule that quenches NAPQI, the 
reactive metabolite of APAP, and scavenges mitochondrial ROS and 
peroxynitrite. We determined GSH levels over a time course of 0 to 24 hr. 
Hepatic GSH levels were similar in OGT KO and WT mice at 0 hr (Fig.2.4.6A). 
Further, both groups had similar depletion of GSH at 1 hr after APAP treatment. 
However, the OGT KO mice had significantly higher and faster replenishment of 
GSH levels as compared to WT mice. The OGT KO mice regained baseline GSH 
level within 6 hr after APAP treatment but the WT mice did not regain baseline 
GSH levels until 24 hr post APAP treatment (Fig.2.4.6A). To determine whether 
rapid GSH replenishment in OGT KO mice is due to induction of genes in the 
GSH biosynthesis pathway, we performed Real Time PCR for Glutamate-
Cysteine ligase regulatory (GCLM) and catalytic (GCLC) subunits. The data 
indicate that both GCLM and GCLC were significantly increased in OGT KO mice 
compared to WT mice 1 and 6 hr (Fig.2.4.6B-C). Furthermore, Glutathione 
reductase (GR), an enzyme important for the recycling of GSH from the disulfide 
(GSSG) form, was also significantly increased in OGT KO mice at 1 and 6 hr 













Fig.2.4.6. OGT KO have rapid replenishment of GSH after APAP overdose (A) 
Hepatic GSH levels and real time PCR of GSH metabolism enzymes (B) GCLC, 
(C) GCLM, and (D) GR in mice treated with 300 mg/kg APAP at 0, 1, 6, 12, 24 hr. 
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TMG increases O-GlcNAc levels in livers of APAP treated mice 
 
Next, we determined the effect of increased O-GlcNAcylation on APAP 
toxicity. Preliminary dose finding studies indicate that 400 mg/kg TMG was a 
suitable dose to induce enhanced hepatic O-GlcNAcylation within 18 hr (data not 
shown). Western blotting indicted that Male C57BL/6J mice treated with 400 
mg/kg dose of TMG 1.5 hr after the administration of a 300 mg/kg dose of APAP 
(Fig2.4.1A) showed increased liver O-GlcNAcylation as compared to mice 
treated with saline (Fig.2.4.1B).  A moderate increase in O-GlcNAcylation was 
observed at 6 hr, which further increased at 12 and 24 hr after APAP treatment 
(Fig2.4.1B).  
 
Increased APAP-induced liver injury in mice with higher O-GlcNAc 
Serum ALT levels and histopathological analysis of H&E stained liver 
sections showed significantly higher APAP-induced liver injury following acute 
TMG treatment (Fig.2.4.7A-B). Serum ALT was significantly increased following 
chronic TMG treatment at 24 hr (Fig2.4.8A). Both serum ALT activities 
(Fig.2.4.7A) and the areas of necrosis (Fig.2.4.7B-C) were significantly higher in 
acute TMG-treated mice with increased O-GlcNAc levels at 6 and 12 hr post-
APAP. Liver injury decreased 24 hr after APAP treatment in both control mice 
and in mice with increased O-GlcNAc levels as demonstrated by the decrease in 














Fig.2.4.7. Increased liver injury in mice with acute increased O-GlcNAc. (A) 
Serum ALT levels in mice treated with APAP+saline and APAP+TMG at 4, 6, 12 
and 24 hr after APAP administration. *Indicates statistically significant difference 
at P<0.05 between the groups at the same time point.  (B) Percent necrosis in 
mice treated with APAP+saline and APAP+400 mg/kg TMG at 4, 6, 12 and 24 hr 
after APAP administration. (C) Representative photomicrographs of H&E stained 
liver sections from APAP+saline and APAP+400 mg/kg TMG treated mice at 6, 







Fig.2.4.8. Increased liver injury in mice with chronic increased O-GlcNAc. (A) 
Serum ALT levels in mice treated with and 50 mg/kg TMG for 2 weeks followed 
by 300 mg/kg APAP and 300mg/kg APAP only at 1, 6 and 24 hr after APAP 
administration. (B) APAP-Cys protein adduct formation in whole liver lysate in 
mice treated with 300 mg/kg APAP at 0, 1, and 6 hr *Indicates statistically 
significant difference at P<0.05 between the groups at the same time point. Real 
time PCR of GSH metabolism enzymes (C) GCLC, (D) GLCM, and (E) GR in 
mice treated 50 mg/kg TMG for 2 weeks followed by 300 mg/kg APAP and 
300mg/kg APAP only at 0, 1, and 6 hr.  
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Sustained increase in hepatic JNK activation in mice with higher O-GlcNAc after 
APAP treatment 
We performed further analysis to determine the mechanisms of increased 
APAP-induced liver injury in mice with higher O-GlcNAc levels. Western blot 
analyses revealed higher JNK activation (increased phosphorylation of JNK) in 
acute TMG-treated mice as compared to control mice at 6 and 12 hr post-APAP 
administration. In control mice JNK activation peaked at 4 hr and declined 
thereafter. However, in acute TMG-treated mice, JNK activation was prolonged 
at least until 12 hr post-APAP treatment (Fig.2.4.9A-B). Further analysis revealed 
higher mitochondrial JNK activation in mice with higher O-GlcNAc at 9 hr post 

































Fig.2.4.9. Increased and sustained JNK activation after acute TMG treatment. 
(A) Western Blot and (B) Densitometry of the blots of total and phosphorylated 
JNK activation using total liver extracts of mice treated with APAP+saline and 




No Change in APAP metabolism after acute TMG treatment 
To determine whether the increase in APAP-induced liver injury observed 
in mice with higher O-GlcNAc is due to increased APAP metabolism, we 
measured three factors indicative of APAP metabolism including hepatic 
CYP2E1 levels, GSH depletion and APAP adduct formation. Western blot 
analysis of total liver lysates obtained from mice treated with acute TMG only at 
400 and 800 mg/kg indicated no change in CYP2E1 expression (Fig.2.4.10A). 
HPLC-based analysis of APAP-protein adducts showed an equal degree of 
protein adduct formation in control mice and in mice with higher O-GlcNAcylation 
due to acute TMG treatment after APAP treatment (Fig.2.4.10B). Chronic 
treatment of TMG resulted in increase in APAP-protein adduct formation at 6 hr 
(Fig.2.4.8B). Analysis of hepatic GSH content revealed significant and similar 
GSH depletion in both control and acute TMG-treated mice following APAP 
treatment. Whereas there was no difference in hepatic GSH content or depletion 
of GSH post APAP treatment, a moderate delay in the recovery of hepatic GSH 
after APAP treatment was observed in acute TMG treated mice between 6 and 
12 hr (Fig.2.4.10C). Consistent with these data, Real time PCR analysis showed 
significant reduction in transcripts of GCLC and GR at 12 hr in acute TMG 
treated mice (Fig.2.4.10D-F). GCLM transcript levels were moderately lower but 
the difference was not statistically significant (Fig.2.4.10E). There was no 
significant difference in GCLC, GCLM, or GR in chronic TMG treated mice, but 






Fig.2.4.10. (A) Western Blot analysis for CYP2E1 using total cell extracts from 
mice treated with 400 or 800 mg/kg TMG dose. (B) APAP protein adducts (C) 
Hepatic GSH levels and in the liver in control mice, mice treated with 
APAP+saline and APAP+400 mg/kg TMG at 0, 4, 6, 12, and 24 hr after APAP 
treatments. Real time PCR of GSH metabolism enzymes (D) GCLC, (E) GLCM, 
and (F) GR in mice treated with APAP+400 mg/kg TMG at 12 hr. *Indicates 









Approximately 50% of all the ALF cases in many western countries are 
associated with overdose of APAP (Lee 1993, Lee 2003, Lee and Seremba 
2008). Despite decades of research, the mechanisms of APAP-induced ALF are 
not completely clear (Jaeschke et al., 2012). Hence the treatment options for 
APAP-induced ALF remain extremely limited (Larson, Polson et al. 2005, Chung, 
Kim et al. 2006). Recent studies have demonstrated that post-translational 
modification of proteins including sumoylation, lysine conjugation, methylation, 
ubiquitination and O-GlcNAcylation play a central role in numerous 
pathophysiologic processes (Schrattenholz, Soskic et al. 2010, Osna, Carter et 
al. 2016, Baker, De Nardo et al. 2017, Martinez, Dias et al. 2017). Importantly, it 
was demonstrated that SIRT3-dependent protein deacetylation enhanced APAP-
induced liver injury (Lu, Bourdi et al. 2011). However, the role of many other 
PTMs in APAP-induced liver injury is currently not known. Here, we demonstrate 
that hepatic O-GlcNAcylation plays a crucial role in APAP hepatotoxicity. Our 
data indicate that increase in hepatic O-GlcNAcylation of proteins results in 
increased APAP-induced liver injury and decreased O-GlcNAcylation inhibits 
APAP-induced liver injury. 
To examine the effects of a decrease in O-GlcNAcylation on APAP-
induced liver injury we deleted OGT, the sole enzyme involved in O-
GlcNAcylation of proteins, specifically in hepatocytes, which resulted in a 
reduction in hepatic O-GlcNAcylation. Our studies showed that OGT KO mice 
displayed a significant reduction in liver injury when compared to WT mice. 
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Consistently, when we increased hepatic O-GlcNAcylation by TMG-mediated 
OGA inhibition, APAP hepatotoxicity was exacerbated. These data suggest that 
O-GlcNAcylation plays a critical role in initiation of APAP-induced liver injury.  
It is known that APAP-induced liver injury involves a cascade of events 
following bio-activation of APAP to NAPQI including increased formation of 
reactive oxygen and reactive nitrogen species, JNK activation, mitochondrial 
damage, and ultimately cellular necrosis (Jaeschke and Bajt 2006, Jaeschke, 
McGill et al. 2012). JNK is activated by phosphorylation at Thr183/Tyr185 by 
upstream MAPK cascade (Seki, Brenner et al. 2012). Previous studies have 
shown that activation (phosphorylation) of JNK is a critical step in APAP-induced 
liver injury (Gunawan, Liu et al. 2006, Henderson, Pollock et al. 2007, Han, 
Shinohara et al. 2010, McGill, Williams et al. 2012). Our studies revealed that 
increasing hepatic O-GlcNAcylation after APAP overdose results in increased 
and prolonged total and mitochondrial JNK activation, which correlates with 
higher hepatic injury. Studies indicate that O-GlcNAcylation of proteins can both 
decrease and increase protein activity (Slawson and Hart 2011). It is possible 
that O-GlcNAcylation further induces hepatic JNK activation following APAP 
overdose and contributes to higher injury. Alternatively, O-GlcNAcylation could 
inhibit phosphatases that have been shown to reduce JNK activation (Wancket, 
Meng et al. 2012, Mobasher, Gonzalez-Rodriguez et al. 2013). 
CYP2E1 is the most important cytochrome P450 enzyme responsible for 
phase two metabolism of APAP (McGill and Jaeschke 2013). Our data showed 
that there was no difference in hepatic CYP2E1 expression (data not shown) or 
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activity following OGT deletion. Further, no difference in basal GSH levels and 
the extent of GSH depletion after APAP treatment in WT and OGT KO mice was 
observed. However, APAP-protein adducts were decreased by approximately 
50% in the OGT KO mice. The decrease in quantity of protein adducts in spite of 
equal CYP2E1 activity and basal GSH levels indicate that O-GlcNAcylated 
proteins may have higher susceptibility to forming APAP-protein adducts. These 
data are consistent with previous observations that protein modifications such as 
acetylation of lysine residues attenuated protein adduct formation and protected 
against APAP hepatotoxicity. Other major mechanisms behind the protection 
observed in OGT KO mice were significantly faster GSH replenishment in OGT 
KO mice following APAP treatment. APAP-induced cell death is critically 
dependent on the mitochondrial oxidant stress and peroxynitrite formation after 
initial GSH depletion and protein adduct formation (Du, Ramachandran et al. 
2016). The lack of GSH during this initial phase substantially impairs the 
antioxidant defense of the cell. Consequently, it was shown that providing 
substrates for GSH synthesis (N-acetylcysteine, GSH) during this time 
accelerates the GSH recovery in the cell, and most importantly in the 
mitochondria, protecting against APAP-induced liver injury (Knight, Ho et al. 
2002, James, McCullough et al. 2003, Saito, Zwingmann et al. 2010). Moreover, 
female mice demonstrate a more pronounced induction of GCLC after APAP 
compared to male mice and the resulting faster recovery of hepatic GSH levels 
makes these female mice much less susceptible to APAP hepatotoxicity than 
male mice (Du, Williams et al. 2014). On the other hand, overexpression of 
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GCLC or GCLM in male mice also renders them less susceptible to APAP-
induced liver injury (Botta, Shi et al. 2006, Botta, White et al. 2008). Together, 
these data demonstrate the importance of the hepatic GSH synthesis capacity as 
a critical determinant of the susceptibility to APAP-induced hepatotoxicity. To 
examine the mechanism behind the rapid replenishment of GSH following OGT 
deletion, we examined expression of the key enzymes in GSH metabolism. The 
data indicate a significant up regulation of three key enzymes in GSH metabolism 
including GCLM, GCLC and GR in the OGT KO mice following APAP treatment. 
These findings explain the faster recovery of hepatic GSH levels and the 
resistance to APAP hepatotoxicity. It is known that the enzymes involved in GSH 
synthesis are regulated by the nuclear receptor NRF2 (Wild and Mulcahy 2000, 
Enomoto, Itoh et al. 2001), which plays a critical role in protection against 
oxidative stress in the liver. Interestingly, recently published data (Chen, Smith et 
al. 2017) and studies from our group have shown that NRF2 is O-GlcNAcylated, 
and the treatment of mice with TMG leads to a loss of NRF2 expression while 
OGT KO animals have an increase in NRF2 expression (Tan, McGreal et al. 
2017). Our data are consistent with this observation and suggest that deletion of 
OGT may reduce O-GlcNAcylation of NRF2 resulting in increased protein levels. 
Stabilization of NRF2 may lead to a rapid induction in GSH biosynthesis genes, 
faster replenishment of GSH and restricting progression of APAP-induced liver 
injury. In the opposite condition, expression of GSH biosynthetic genes is down 
regulated in TMG-treated mice, which have higher O-GlcNAcylation. Taken 
together, these data indicate that NRF2 activity is regulated by O-GlcNAcylation, 
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which in turn regulates GSH replenishment and the extent of APAP-induced liver 
injury. 
Collectively, The data presented in this study are significant because 
chemicals that increase O-GlcNAcylation, and specifically TMG, are being tested 
as therapeutic agents for neurological disorders including Alzheimer’s disease 
(Macauley and Vocadlo 2010). Another issue is potential interaction of APAP 
with the dietary supplement glucosamine. The availability of O-GlcNAc is 
controlled by flux through the hexosamine biosynthetic pathway (HBP) (Teo, 
Wollaston-Hayden et al. 2010).  Glucose enters this pathway and is converted to 
UDP-GlcNAc, the metabolite for OGT. Glucosamine feeds directly into the HBP, 
skipping the initial step, and can result in increased O-GlcNAcylation. This is 
important because glucosamine is a popular dietary supplement used for its 
perceived benefits for arthritis and joint pain (Miller and Clegg 2011). The 
addition of glucosamine to a pain regimen that already includes APAP could 
potentially be hazardous. Our data suggests that any therapeutic interventions 
that increase O-GlcNAcylation should be carefully tested for its safety, drug-drug 
interactions and possible hepatotoxic effects; while methods to decrease cellular 
O-GlcNAc might be promising new therapeutics targets for the treatment of 
APAP overdose and APAP-induced liver injury. 
 In conclusion, our data demonstrate that decreasing hepatic O-
GlcNAcylation, a ubiquitous PTM of key proteins, drastically reduced the toxic 
effects of APAP by a dual effect. First, reduced O-GlcNAcylation attenuates 
targets for protein adduct formation and second, the promotion of GSH recovery 
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enhances the scavenging capacity for ROS and peroxynitrite in mitochondria. 
These studies have revealed a novel pathway that critically affects not only 
APAP-induced liver injury but also highlighted a possible causal role of O-
GlcNAcylation in drug- and chemical-induced liver injury where oxidative stress is 








Chapter 3- Decreased O-GlcNAcylation by hepatocyte specific deletion of 














O-GlcNAcylation is the covalent attachment of a single sugar N-acetyl- 
glucosamine (O-GlcNAc) sugar to a Ser/Thr residue of a protein. O-GlcNAc 
transferase (OGT) is the enzyme that adds O-GlcNAc moieties to proteins, While 
O-GlcNAcase (OGA) removes O-GlcNAc moieties from proteins. O-
GlcNAcylation has extensive crosstalk with protein phosphorylation and because 
of this it plays a critical role in cell signaling involved in cell proliferation and 
differentiation. However, the role of O-GlcNAc in liver regeneration is not known. 
In this study, we examine the role of O-GlcNAc in liver regeneration after partial 
hepatectomy (PHX) following hepatocyte specific deletion of OGT in mice. WT 
mice had a normal regenerative response with peak proliferation at 48 hr after 
PHX, which subsided by 7 days and regeneration was complete at 14 days post 
PHX. OGT KO mice had a similar profile of cell proliferation up to 48 hr but 
exhibited significantly higher cell proliferation at 5, 7, and 14 days as compared 
to WT mice. Even at 14 days post PHX, substantial number of cells were 
proliferating in the OGT KO mice, which resulted in significantly higher liver to 
body weight ratio. The increased proliferation was secondary to an increase in 
Cyclin D1, pRb and CDK4 protein levels in later time points when compared to 
WT mice. Several signaling pathways critical for hepatocyte proliferation and 
known to be involved in cancer pathogenesis remained active in OGT KO mice 
significantly longer than in WT mice. Taken together, these data indicate that 
hepatic O-GlcNAcylation plays a critical role in regulation of cell cycle after PHX, 
loss of which results in termination of liver regeneration.  
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3.2 Introduction 
O-linked β-N-acetyl glucosamine (O-GlcNAc) is a single sugar 
posttranslational protein modification covalently attached to a hydroxyl group of 
Ser or Thr residue of a nuclear, cytoplasmic or mitochondrial protein (Zachara, 
O'Donnell et al. 2004, Slawson, Copeland et al. 2010). O-GlcNAc is added to a 
protein by a single enzyme, O-GlcNAc transferase (OGT), in a process called O-
GlcNAcylation. In the reverse reaction, a single enzyme called O-GlcNAcase 
(OGA) performs the removal of O-GlcNAc from a protein. The cellular source of 
O-GlcNAc is the flux of 2-3% of the glucose intake through the hexosamine 
biosynthetic pathway (HPB) to form the high-energy donor substrate UDP-
GlcNAc (Slawson, Copeland et al. 2010, Bond and Hanover 2015). HBP is at the 
intersection of several other key pathways including the metabolism of 
carbohydrates, fats, amino acids, and nucleotides; this makes HBP flux, and thus 
O-GlcNAcylation, very sensitive to metabolite availability and nutrient flux (Bond 
and Hanover 2015). O-GlcNAcylation has been shown to have extensive 
crosstalk with protein phosphorylation (Slawson and Hart 2003). When O-GlcNAc 
is elevated in mammalian cells, 70% of phosphorylation sites are affected, 
making it extremely important in signaling cascades and enzyme function (Wang, 
Gucek et al. 2008).   
O-GlcNAcylation is shown to regulate many cellular processes including 
cell growth and cell survival (Slawson and Hart 2011). O-GlcNAc also plays a 
pivotal role in the cell cycle and cell cycle progression (Slawson, Zachara et al. 
2005). Elevated O-GlcNAc is shown to be a key regulator of mitotic 
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phosphorylation and overexpression of either OGT or OGA disrupts cyclin 
periodicity leading to improper cytokinesis and cell growth delays in many cell 
types (Slawson, Zachara et al. 2005). A deletion of OGT in mouse embryonic 
fibroblasts leads to an increased expression of the cyclin inhibitor p27 and growth 
delays (Zachara, O'Donnell et al. 2004). The reduction of OGA leading to an 
increase in O-GlcNAc was shown to promote mitotic spindle formation defects 
(Tan, Caro et al. 2013, Lanza, Tan et al. 2016), and a knockdown of OGA in 
HeLa cells caused a prolonged M phase with shortened spindle chromatids and 
increased multi-pole spindles (Lanza, Tan et al. 2016). The process of O-
GlcNAcylation is tightly regulated and any alteration is O-GlcNAc cycling has a 
profound effect on the cell cycle.   
The liver has an innate ability to regenerate, which plays a critical role in 
maintaining liver homeostasis (Michalopoulos 2017). Liver regeneration after 
partial hepatectomy (PHX), the most commonly used model of liver regeneration, 
is regulated by precise and orderly signaling events. During Liver regeneration, 
first the hepatocytes followed by other hepatic cells in the remnant liver lobes 
undergo cellular proliferation to restore the liver mass (Michalopoulos 2007). 
After PHX, the liver regains its pre-hepatectomy mass and function within 7 to 14 
days in rodents (Apte, Gkretsi et al. 2009).  
Due to the role O-GlcNAc in cell cycle progression and cyclin expression 
we set out to examine the role of O-GlcNAc in liver regeneration using partial 
hepatectomy (PHX) as a model and hepatocyte specific OGT knockout (OGT 
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KO) mice. Our results have revealed a novel role of this ubiquitous 




3.3 Materials and Methods 
Animal and Tissue Preparation 
Animal studies and procedures were approved and performed in 
accordance with the guidelines set forth by the Institution of Animal Care and 
Use Committee at the University of Kansas Medical Center. OGT- floxed (OGTF) 
mice (Shafi, Iyer et al. 2000) were provided by Natasha Zachara from the Johns 
Hopkins University School of Medicine. 2-3 month old male OGTF mice (n=3-5 
per group per time point) were injected i.p. with AAV8.TBG.PI.Cre.rBG (Penn 
Vector Core, Philadelphia, PA) at 5E11 virus particles per mouse to initiate Cre-
mediated deletion of OGT. 10 days after deletion, partial hepatectomy (PHX) was 
performed as previously described (Apte, Gkretsi et al. 2009). OGT deletion was 
confirmed in all OGT KO mice after sample collection using Western blot. 
Surgeries occurred between 9 AM and 11 AM. Mice were euthanized by cervical 
dislocation under isoflorane over a timecourse from 0 day – 14 days. Livers were 
harvested and embedded in paraffin.  
 
Western Blot Analysis 
Western blot analysis of isolated proteins was performed as previously 
described (Borude, Edwards et al. 2012). Briefly, frozen liver tissue was taken 
out of storage in the -80°C and solubilized in RIPA buffer. 100 µg of protein was 
loaded onto a Bis-Tris 4-12% gel (Invitrogen) and ran for 90 minutes at 150V. 
Proteins were transferred to PVDF (Millipore) and stained with primary antibodies 
purchased from Cell Signaling. Antibodies can be seen in the table below.  
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Primary Antibody  Company Product No. 
Cyclin A2 Cell Signaling  4656 
Cyclin B1 Cell Signaling 4135 
Cyclin D1 Cell Signaling 2978 
CDK4 Cell Signaling 12790 
CK19 Proteintech 10712-I-AP 
EGRF Cell Signaling 4267 
p-EGFR Cell Signaling 2237 
Erk Cell Signaling 4695 
p-Erk Cell Signaling 4370 
GAPDH Cell Signaling 2118 
GSK3β Cell Signaling 5676 
p- GSK3β Cell Signaling 5558 
HNF4α Perseus Proteomics PP-H1415-00 
PNCA Cell Signaling 2586 
p-Rb Cell Signaling 8516 
Yap Cell Signaling 14074 




4 µm thick paraffin sections of liver were cut and PCNA, CK19 and H&E 
staining was performed as described previously (Borude, Edwards et al. 2012). 
H&E staining was done on a Leica Autostainer XL and CV5030 cover slipper. 
Briefly, slides stained for PCNA and CK19 were de-parafinized and boiled in 
citrate buffer for antigen retrieval. Antibodies were applied to the slides, and 
antibodies on slides were visualized using Vectastain ABC kit (Vector) and DAB 
peroxidase substrate kit (Vector). Slides were counter stained with hematoxylin 
and blued in Bluing Reagent (RICCA Chemical Company). All antibodies used 





Total RNA was isolated from mouse liver tissue using TRIZOL. Mice from each 
group were pooled (n= 3-5) and sent to the KUMC genomics core facility for 
RNA-Seq analysis on an Illumina HiSeq 2000 (Illumina. San Diego, CA) and 
bioinformatics analysis was performed as previously described (Walesky, 







OGT KO Mice have an increased liver to body weight ratio after PHX 
Liver weight to body weight ratio of control mice plateaus at 7 days, while 
the OGT KO mice continues to increase to 14 days (Fig.3.4.1). This shows that 
OGT KO mice have an increase in liver regeneration when compared to control 
mice.   
 
OGT KO mice have a change in cell morphology 
H&E staining shows that OGT KO mice and control mice have similar liver 
morphology before PHX. However, at 14 days after PHX, the livers of OGT KO 
mice show an increase in vacuolization of cells as characterized by a loss of 


















Fig.3.4.1. Liver to Body Weight Ratio. After PHX the liver regenerates to full 
mass on a time course of 0-14 days. OGT KO mice show increased liver 
regeneration compared to OGT WT mice. * Indicates statistical significant 



















Fig.3.4.2. H&E immunohistochemistry. Time course of 0-14 days shows a 




Termination defect in OGT KO in liver regeneration after PHX 
In order to further examine the effects of OGT KO on liver regeneration 
after PHX, we examined several proteins critical in cell cycle progression and the 
regenerative response. Western blot analysis shows that Cyclin D1 expression 
was equal between WT and OGT KO mice up to 72 hr after PHX. However, OGT 
KO mice exhibited significantly higher Cyclin D1, A2 and B1 protein expression at 
7 and 14 days when compared to WT mice (Fig.3.4.3). This was also observed 
with CDK4, pRb and PCNA expression. During the first 3 days (72 hr), these 
proteins were expressed at a comparable level in WT and OGT KO mice. 
However, the OGT KO mice had a significant increase in CDK4 at 14 days, in p-
Rb at 5, 7 and 14 days and in PCNA protein at 5, 7 and 14 days after PHX 
(Fig.3.4.3). PCNA protein increase was also confirmed by immunohistochemistry 
showing an increase in PCNA positive cell at 7 and 14 days post PHX (Fig.3.4.4). 
Taken together, these data show that OGT KO mice have an extended cell 













Fig.3.4.3. OGT KO leads to increased regeneration. Western blot analysis using 
total liver homogenate showing the increase in Cyclin D1, CDK4, p-Rb and 






Fig.3.4.4. PCNA immunohistochemistry. Representative image of PCNA 
immunohistochemistry after PHX for OGT KO and OGT WT mice over a time 
course of 0-14 days. 
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OGT KO mice have an increase in signaling associated sustained proliferation 
To determine the mechanisms of sustained proliferation in OGT KO mice 
after PHX, we determined changes in EGFR signaling, known to be a primary 
driver of hepatocyte proliferation (Michalopoulos 2007). Western blot analysis 
revealed that EGFR protein expression was elevated at 14 days in the OGT KO 
mice. Activation of EGFR as shown by p-EGFR was also increased at 14 days 
(Fig.3.4.5). Since we observed a marked defect in termination of regeneration, 
we investigated two other proteins involved in this process included Yes 
associated protein (YAP), the downstream regulator of Hippo Kinase pathway, 
and HNF4a, the master regulator of liver differentiation. We observed that YAP 
activation as measured by ratio of total YAP to phosphorylated (inactive) YAP, is 
significantly higher in OGT KO mice at 14 days post PHX (Fig.3.4.5). 
Additionally, we observed a significant decrease in HNF4α protein expression in 
OGT KO mice at 14 days after PHX (Fig.3.4.5). All these changes in cell 
signaling are indicative of an increase in liver regeneration and a loss of 
termination signal for the liver in the OGT KO, leading to increased liver growth at 
14 days. RNA-seq data shows an increase in fold change of most negative 
targets and a decrease in fold change of most positive targets of HNF4α at 14 











Fig.3.4.5. OGT KO leads to increased cell signaling. Western blot analysis of 
total liver protein lysates showing a variety of critical signaling proteins involved 
























































Fig.3.4.6. RNA-Seq fold change data of positive and negative targets of HNF4α. 
  
 
Known Targets of HNFα 
 


























OGT KO mice have an increase in CK19 
Histopathological analysis of livers from OGT KO mice at 7 and especially 
14 days after PHX indicated presence of small cells with oval nuclei, which 
resembled oval cells. An oval cell is a term used to described hepatic progenitor 
cells, which normally do not contribute to liver regeneration. We further sought to 
determine activation of hepatic progenitors in OGT KO mice during PHX and 
stained paraffin sections for CK19, a marker used to identify both hepatic 
progenitors and cholangiocytes. OGT KO mice showed an increase in CK19+ 
cells at 14 days as shown by immunohistochemistry. OGT WT mice show CK19 
only on the bile duct, While OGT KO mice have cellular staining of CK19 not 
associated with bile duct cells (Fig.3.4.7).  The significance of these findings 
remains to be appreciated and significant additional studies are needed to 
















Fig.3.4.7. CK19 immunohistochemistry. A representative image of CK19 






 The liver has a remarkable ability to regenerate after partial resection and 
following drug induced liver failure (Michalopoulos and DeFrances 1997). In this 
study we utilize partial hepatectomy (PHX) model, where 60-70% of the liver is 
surgically resected to study effect of OGT deletion on liver regeneration. PHX 
allows the study of liver regeneration without necrosis or inflammation, making it 
an ideal tool to study regenerative organ growth (Michalopoulos 2010). The time 
course of signaling following PHX is precise and orderly, starting within the first 
few minutes post-PHX and continuing to 7-14 days after surgery (Michalopoulos 
2007). The reproducibility and precise nature of the PHX model make it an ideal 
tool for studying liver regeneration. Interestingly, much is known about initiation 
of liver regeneration but the mechanisms of termination of liver regeneration are 
not well understood. Determining the factors involved in the termination of liver 
regeneration could hold the key to deciphering hepatocellular carcinoma (HCC) 
pathogenesis.  
The deletion of OGT in mice, and the subsequent reduction of O-
GlcNAcylation, results in increased hepatocyte proliferation and a loss in the 
termination signal of liver regeneration. Liver regeneration in OGT KO mice 
follows a similar pattern to OGT WT mice during the initial phase of liver 
regeneration up to 2 days post PHX. By 7 days there is change in cell 
morphology in OGT KO mice and cell proliferation continues until 14 days. These 
data demonstrate that decrease in O-GlcNAcylation by deletion of OGT results in 
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a termination defect following PHX and suggest a role for O-GlcNAcylation in 
inhibition of proliferation and re-differentiation of hepatocytes. 
  We also observed a decrease in HNF4α protein levels as shown by 
Western blot in OGT KO mice as compared to WT mice at 14 days following 
PHX (Fig.3.4.5). Previous studies have shown that HNF4α can suppress 
hepatocyte proliferation and a deletion of HNF4α can lead to increase 
proliferation and cancer (Bonzo, Ferry et al. 2012, Walesky, Gunewardena et al. 
2012, Walesky, Edwards et al. 2013). Further, HNF4a is necessary not only to 
maintain hepatic differentiation but also to induce re-differentiation of hepatocytes 
following PHX (Huck, Manley Jr. et al. 2015, Huck, Manley Jr. et al. 2016). 
Decrease in HNF4a expression partially explains the termination defect in OGT 
KO mice.  
We also observed a significant increase in YAP activity in OGT KO mice 
at 14 days after PHX. YAP is a known to help maintain organ size and is crucial 
for development (Zhao, Tumaneng et al. 2011). The phosphorylated form of YAP 
(p-YAP) is the inactive form of YAP and gets targeted for degradation. It has 
been shown previously that a loss of Mst1/2, the proteins that phosphorylate 
YAP, leads to liver overgrown and cancer (Zhou, Conrad et al. 2009). We 
observed a decrease in p-YAP in OGT KO mice indicating a suppression of 
Hippo/Yap signaling, which inhibits liver size expansion. Taken together these 
data point to OGT KO altering the dynamics of the termination phase of liver 
regeneration by promoting growth and suppressing the signal to terminate 
regeneration. 
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Recent studies have shown that EGFR signaling is essential for proper 
liver regeneration (Michalopoulos and DeFrances 1997, Paranjpe, Bowen et al. 
2016). The ligands of EGFR, TGFa and EGF are primary mitogen of liver 
regeneration along with HGF (Block, Locker et al. 1996) and are critical in liver 
growth and regeneration (Mullhaupt, Feren et al. 1994). We observed that both 
EGFR and p-EGFR are elevated in OGT KO mice after PHX. This elevation of 
EGFR and p-EGFR is leading to an increase in liver regeneration after PHX. The 
fact that p-EGFR is elevated at 14 days post PHX in OGT KO mice also leads to 
the conclusion that the OGT KO mice liver is still growing. It is possible that 
several important proteins involved in signaling during liver regeneration and the 
termination of regeneration might be O-GlcNAcylated. In our model, the loss of 
O-GlcNAcylation due to OGT KO may be altering the activity and expression of 
these proteins leading to drastic changes in the signaling pathways important for 
liver regeneration.  
 In our study, we show that OGT KO, and thus a decrease in O-
GlcNAcylation, leads to an increase in PCNA, Cyclins A2, B1 and D1 during 
termination phase of liver regeneration (7 and 14 days post PHX). RNA-seq data 
also showed an increase in fold change of the cyclins in OGT KO over WT. It is 
known that O-GlcNAcylation is an important regulator of the cell cycle and cell 
cycle progression. Elevation of O-GlcNAc was shown to reduce cell growth rates 
and lead to a delay in G2/M progression of the cell cycle in several cell lines, 
while decreased O-GlcNAc delays mitotic phosphorylation and alters cyclin 
expression (Slawson, Zachara et al. 2005). In another study, overexpression of 
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OGT was shown to decrease CDK1, the master regulator of M phase (Wang, 
Udeshi et al. 2010). These studies all show that the increase in O-GlcNAcylation 
leads to poor progression through the cell cycle and cell cycle delays. When 
coupled with our study showing a decrease in O-GlcNAcylation leads to an 
increase in cell cycle markers and cell proliferation, a clear role of O-
GlcNAcylation and cell cycle progression is evident.  
Taken together, the increase in pro-regenerative signaling and loss of 
termination signals result in sustained proliferation in OGT KO. These data show 
that OGT and O-GlcNAcylation are required for proper liver regeneration after 
PHX. This could prove to be of critical importance in HCC pathogenesis. It is 
known that signals that drive liver regeneration and those that drive proliferation 
in HCC are similar. However, pro-mitogenic signaling is precisely regulated and 
turned off at a specific time during liver regeneration thanks to effective 
termination and re-differentiation signals. In HCC, the pro-mitogenic signals 
remain active partly due to defect in termination signals. Our data indicate that 
loss of OGT function or decrease in O-GlcNAcylation could increase the 
likelihood on developing HCC. Whereas further research is necessary, this study 
shows that any alteration in the levels of O-GlcNAcylation can have profound 

































O-GlcNAcylation is the covalent addition of a single N-acetyl glucosamine 
(O-GlcNAc) to a serine or threonine residue of a nuclear, cytoplasmic or 
mitochondrial proteins (Zachara, O'Donnell et al. 2004, Slawson, Copeland et al. 
2010). O-GlcNAcylation is a dynamic intracellular process and, unlike other forms 
of glycosylation, there is no chain elongation (Slawson and Hart 2011). Despite 
the lack of a consensus sequence for binding, over 4000 protein are known to be 
O-GlcNAcylated (Ma and Hart 2014). O-GlcNAc has been implicated in many 
cellular processes and diseases including cell cycle regulation (Slawson, 
Zachara et al. 2005, Tan, Caro et al. 2013), cancer pathogenesis (Slawson and 
Hart 2011), and stress response (Zachara, O'Donnell et al. 2004). Despite the 
multitude of cellular processes that involve O-GlcNAc, very little work has been 
done on liver injury and regeneration. In this study, we examined the role of O-
GlcNAc in acute liver injury after APAP and in liver regeneration after PHX.  
It is known that approximately 50% of all the ALF cases in the developed 
countries are associated with overdose of APAP (Lee 1993, Lee 2003, Lee and 
Seremba 2008). Although APAP overdose is common, the mechanisms of 
APAP-induced ALF are not completely clear, because of which the treatment 
options for APAP-induced ALF remain extremely limited (Larson, Polson et al. 
2005, Chung, Kim et al. 2006). Recent studies on the effects of post-translational 
modifications (PTMs) have demonstrated that PTMs of proteins such as 
sumoylation, lysine conjugation, methylation, ubiquitination, and O-GlcNAcylation 
play a central role in pathophysiology including stress response (Schrattenholz, 
Soskic et al. 2010).  However, the role of many of these PTMs in APAP-induced 
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liver injury is currently not known. This lack of knowledge on the roles of PTMs 
represents a knowledge gap that needs to be bridged. In this study, we show that 
O-GlcNAcylation plays a central role in APAP induced liver injury and that 
modulation of O-GlcNAc levels not only has a profound effect on the safety of 
APAP but could also be used an intervention for APAP overdose. 
In order to determine the role that O-GlcNAcylation plays in acute liver 
injury, we used the acetaminophen overdose model combined with both gain of 
function and loss of function approaches. The gain of function approach involved 
an increase in O-GlcNAcylation by pharmacological intervention using Thiamet-G 
(TMG), a potent inhibitor of O-GlcNAcase (OGA). The loss of function approach 
involved a decrease in O-GlcNAcylation using a hepatocyte specific deletion of 
O-GlcNAc transferase (OGT). In the TMG model (increased O-GlcNAcylation 
model) there was an increase in APAP-induced liver injury following both the 
acute and chronic treatment of TMG-mediated increased O-GlcNAcylation. 
Consistently, the OGT KO mice (the decreased O-GlcNAcylation model) showed 
a resistance to APAP induced liver injury. The decreased APAP-induced liver 
injury in OGT KO mice was accompanied by an increase in the ability of 
glutathione (GSH) recovery due to an up-regulation of antioxidant defense 
genes. Consistently, the expression of the GSH biosynthesis genes was 
decreased following TMG treatment. Further, our studies in collaboration with Dr. 
Slawson’s group showed the modulation GSH biosynthesis genes by O-
GlcNAcylation via changes in NRF2 expression. NRF2 is known to be the master 
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regulator of antioxidant response genes and the enzymes involved in GSH 
synthesis. (Wild and Mulcahy 2000, Enomoto, Itoh et al. 2001).  
The results of our study show that there is a relationship with the level of 
O-GlcNAcylation and the susceptibility to APAP, and this relationship is 
mechanistically relevant to APAP toxicity. Our results show that OGT KO mice 
have an increased ability to recover glutathione (GSH) after APAP injury. GSH is 
an important molecule in response to oxidative stress. The importance of GSH to 
the recovery of APAP induced liver injury has been well established (Muldrew, 
James et al. 2002, Bajt, Knight et al. 2004). In the case of APAP, there is a 
massive increase in oxidative stress and mitochondrial damage that is observed 
in APAP injury (Jaeschke, McGill et al. 2012). When put together it is evident that 
O-GlcNAcylation is a crucial part of the response to APAP toxicity, and by 
controlling O-GlcNAcylation is may be possible to alter the profile of APAP 
toxicity. To date no work on APAP toxicity has been performed using OGA KO 
mice (Keembiyehetty, Love et al. 2015), but this could provide even more 
evidence that O-GlcNAcylation is critically important for the safety of APAP.  
O-GlcNAcylation is an essential cellular process. The deletion of either 
OGT or OGA, the enzymes that regulate O-GlcNAcylation is embryonic lethal 
(Shafi, Iyer et al. 2000, Keembiyehetty, Love et al. 2015). Previous studies have 
shown that O-GlcNAc is increased in response to heat stress (Sohn, Lee et al. 
2004, Zachara, O'Donnell et al. 2004), ischemia reperfusion injury in the heart 
(Champattanachai, Marchase et al. 2008, Jones, Zachara et al. 2008) and 
inflammation in the heart (Xing, Feng et al. 2008). These studies all point to a 
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protective pro-survival role of increased O-GlcNAcylation in response to stress, 
but our results show that an increase in O-GlcNAcylation exacerbates APAP 
induced liver injury. A reason for the apparent contradiction could be that the 
effects of O-GlcNAcylation are context specific; meaning alterations in O-
GlcNAcylation profile might be dependent on not only the type of stress but also 
the stressor. The fact that our results are paradoxical to what is known about O-
GlcNAcylation and other stress responses makes it clear that this more work 
needs to be done to understand the role of O-GlcNAcylation in APAP overdose.   
The other physiological process significantly affected by O-GlcNAcylation 
is cell proliferation. However, the role of O-GlcNAcylation in regulating cell 
proliferation in the liver is not known. We investigated the effects of decreased O-
GlcNAcylation on liver cell proliferation using the partial hepatectomy (PHX) 
model in the OGT KO mice. Liver regeneration after PHX is a well-studied model 
and it involves matrix remodeling, growth factor signaling and hepatocyte 
proliferation (Michalopoulos and DeFrances 1997). Since the events occur in an 
orderly and predictable fashion, it is easy to examine the effects of different 
factors on the overall ability of the liver to regenerate after PHX. Our studies 
showed that decrease in O-GlcNAcylation results in continued cell proliferation in 
the liver well beyond the 3-5 day post-PHX window observed in WT mice. The 
increase in liver size and the preponderance of signaling molecules important for 
liver regeneration that are unregulated after PHX in OGT KO mice stress that O-
GlcNAcylation is essential for effective termination of liver regeneration. Due to 
the large increase in regeneration after OGT KO this study also provides 
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evidence that modulation of O-GlcNAc could be a potential therapeutic 
intervention for cancer, possibly by treating with the potent OGA inhibitor TMG. A 
potential future direction would be to perform OGT KO and OGA KO and induce 
hepatocellular carcinoma (HCC) with the treatment of diethyl nitrosamine.    
There is a potential that key signaling molecules important for proper liver 
regeneration are in fact O-GlcNAcylated, which in turn would regulate their 
activity. Previous studies have shown that O-GlcNAcylation of proteins is critical 
to their function, by either promoting activation or ensuring deactivation. In 
pancreatic cancer cells, hyper-O-GlcNAcylation was shown to increase the 
activity of NFĸB p65 subunit and the upstream kinases IKKα and IKKβ, while 
reducing hyper-O-GlcNAcylation lead to loss of p65 nuclear translocation and 
subsequent target gene expression (Ma, Vocadlo et al. 2013). NFĸB was shown 
to be required for hepatocyte proliferation after PHX in mice after a deletion of 
NEMO, a modifier of NFĸB, and this also lead to an increase in oxidative stress; 
but there was compensatory regeneration from hepatic oval cells (Malato, 
Ehedego et al. 2012). The loss of NFĸB through a targeted deletion of its 
upstream kinase IKKβ triggers the immune response and leads to earlier cell 
proliferation during liver regeneration (Malato, Sander et al. 2008). NFĸB is just 
one of many proteins important for liver regeneration whose function is controlled 
by O-GlcNAcylation. Determining the role O-GlcNAc plays in the signaling during 
liver regeneration represents an untapped frontier in liver regeneration, and O-
GlcNAcylation of NFĸB is just one signaling protein that can be examined in the 
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context of liver regeneration after either an increase or decrease in protein O-
GlcNAcylation in the future.    
We observed a significantly sustained and up regulated proliferative 
response following PHX in OGT KO mice. In the cell cycle, E2F family of 
transcription factors is essential to transition the cell from G1 to S phase of the 
cell cycle. In order for E2F to be activated, Cyclin D1 must bind CDK4 which in 
turn phosphorylated Rb protein leading to the inactivation of Rb (Dimova and 
Dyson 2005). Previous studies have shown that Rb function is controlled by O-
GlcNAc (Wells, Slawson et al. 2011) and that and the overexpression of E2F-1 
negatively regulates OGT (Muthusamy, Hong et al. 2015). Overexpression of 
OGT was shown to decrease CDK1 activity, the master regulator of M-phase 
progression (Wang, Udeshi et al. 2010). O-GlcNAcylation, or more specifically 
the proper balance of O-GlcNAcylation, is immensely important for cell cycle 
progression. It was shown previously that overexpression of either OGT or OGA 
causes disruption in cyclin periodicity and causes improper cytokinesis (Slawson, 
Zachara et al. 2005). These studies point to an integral role of O-GlcNAc in 
maintaining the cell cycle. In the context of OGT KO, it should not be surprising 
that loss of OGT and subsequent ablation of O-GlcNAcylation leads to aberrant 
liver regeneration after PHX. In our study, there was a significant and sustained 
increase in Cyclin D1, A2, B1 and p-Rb, as well as a large increase in PCNA 
positive cells in OGT KO mice, which is evidence of an increase flux through the 
cell cycle.  
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Our study also shows there is an increase in CK19 at 14 days post PHX. 
In the normal human liver CK19 is expression in the bile duct epithelium 
(Lemaigre 2015). Expression of CK19 is also seen in hepatic progenitor cells or 
oval cells (Wang, Foster et al. 2003). The existence of CK19 staining in OGT KO 
livers outside of the biliary epithelium suggests that there might be oval cell or 
biliary cell expansion and proliferation in the livers of OGT KO mice after PHX, 
with a potential outcome being cancer. Future studies are needed to examine the 
role of the presence of CK19 outside the biliary epithelium in OGT KO livers and 
determine if OGT KO alters the bile duct and bile flow, or if prolonged 
regeneration leads to liver cancer due to OGT KO.   
O-GlcNAcylation of transcription factors has been shown to influence their 
activity, DNA binding, stability and interaction with co-factors (Ozcan, Andrali et 
al. 2010). The O-GlcNAcylation of p53 has been shown to decrease 
phosphorylation and subsequent ubiquitination, leading to a more stable p53 by 
blocking proteolysis (Yang, Kim et al. 2006). As a known tumor suppressor, p53 
plays a critical role in stabilizing cells under stress due to its anti-proliferation 
capacity. In our OGT KO model of liver regeneration there is prolonged 
hepatocyte proliferation, with the number of PCNA positive cells remaining 
increased at 14 days post PHX. This suggests that there might be a role for p53 
in the OGT KO model of liver regeneration where p53 is suppressed in OGT KO 
mice during liver regeneration; but future studies would need to be conducted to 
confirm a role for p53.  
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Overall, our studies show that alterations in O-GlcNAcylation play an 
important role in both drug-induced liver injury after APAP overdose and liver 
regeneration after PHX. The work done provides insight into an area of study that 
has not been studies previously, and shown a new role for O-GlcNAc. It also 
points to the importance of maintaining appropriate levels of protein O-
GlcNAcylation for proper regulation of protein function. The work done here has 
provided an insight into the role of O-GlcNAc in APAP induced liver failure that 
could potentially lead to a therapeutic intervention. A potent inhibitor of OGT 
could potentially be used as a treatment for APAP in conjugate with  
N-acetylcysteine. We have also highlighted the role of O-GlcNAc in liver 
regeneration and shown that a decrease in O-GlcNAcylation leads to a loss of 
liver regeneration termination signal and an increase in hepatocyte proliferation. 
These data could have a profound effect on how we view cancer pathogenesis. It 
might be possible to treat HCC patients with TMG, a potent OGA inhibitor, and 
slow down the progression of cancer. Although this study points to a role in O-
GlcNAcylation in many signaling cascades after PHX, the exact mechanisms are 
not known. An important future direction for this project would be to determine 
which pathways are being up regulated or down regulated in the OGT KO mice 
during regeneration. Another important future direction would be to determine the 
role of OGT KO on the metabolism of glucose and glycogen storage in the liver 
following both APAP induced liver injury and liver regeneration after PHX. This 
would lead to a more complete understanding of the role of O-GlcNAcylation in 
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the liver. In conclusion, this study has shown a novel role for O-GlcNAc in the 
liver, and stressed the importance of maintaining a balance in O-GlcNAcylation.      
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